explore -WSS

explore

author：hotspot 2025-10-01 01:50:39 - browse：5658

BRENDAN SMIALOWSKI/AFP via Getty Images

A New York jury on Wednesday convicted the former CEO of Stimwave, a company that sold devices with dummy pieces of plastic, on two counts of health care fraud. The maximum jail sentence for each count is 20 years.

Laura Perryman led Stimwave, which sold nerve stimulation devices to combat pain, from 2010 to 2019. Under her leadership, Stimwave distorted the design of the device to better fit insurance codes, resulting in unnecessary plastic components that allowed the company to sell its products for thousands of dollars more than it otherwise could. From 2017 to 2020, the company sold nearly 8,000 devices with the non-functioning component.

STAT published new details about the Stimwave story last May, after former employees described how Perryman broke into Stimwave’s Florida headquarters to steal back devices after her termination in 2019. The fraud laid bare the limits of the Food and Drug Administration’s device surveillance system, doctors’ ability to scrutinize device effectiveness, and how impossible it is for patients to get answers about the implants they receive.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： Stop Congress from blocking public access to science

knowledge

entertainment

WSS

Commercial surrogacy can be ethical, despite pope’s claims

Vertex non

Lawsuit highlights wrinkle for disputes over surprise medical bills

Quicker fix for pulse oximeters urged during FDA public meeting

SAMSHA loosens regulations on methadone treatment centers

The biotech scorecard for Q4: 16 stock

knowledge

explore

knowledge

Medicare proposal to cover medical devices draws a mixed reaction

Some top drug companies are starting to take action on climate

Bright Health sells Medicare Advantage business to Molina

Quicker fix for pulse oximeters urged during FDA public meeting

State Dept. review finds Biden bears some blame for Afghanistan failures

The lessons of Aduhelm, an Alzheimer's drug that was not to be

Heart attack and stroke risk calculators need revising

Readout Newsletter: Vertex, Biogen's Aduhelm, and Bristol updates

FDA approval of Sarepta Duchenne genetic therapy gives me hope

European officials brace for rough respiratory virus season

focus

Cybersecurity threat forces Lurie Children's to take systems offline

Health insurers' Q3 question: how much care are people getting?

Apple Vision Pro: A first look at health apps on the new VR headset

WHO recommends second malaria vaccine

Experts study whether long Covid risk adds up with each reinfection

Readout Newsletter: Vertex, Biogen's Aduhelm, and Bristol updates

knowledge

entertainment

leisure time

focus